Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors

NEW YORK, July 14, 2025 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. (“Capricor”) common stock (NASDAQ: CAPR). Capricor is a clinical-stage drug company and its lead product candidate is Deramiocel, which is used to treat cardiomyopathy, a weakening of the heart in people with Duchenne muscular dystrophy. Capricor’s Phase 2 HOPE-2 clinical trial was completed in 2021. On September 24, 2024, Capricor announced it was filing a Bio ...